

Neonatal sepsis with neutropenia: granulocyte colony stimulating factor (G-CSF)

 Antonio Silvinato¹
 Wanderley Marques Bernardo²
Idevaldo Floriano¹
Gabriel Nogueira Bastos Soledade¹

1. Programa Diretrizes da Associação Médica Brasileira, São Paulo, SP, Brasil.
2. Coordenador do Programa Diretrizes da Associação Médica Brasileira, São Paulo, SP, Brasil.

<http://dx.doi.org/10.1590/1806-9282.66.4.400>

Question: What is the impact on overall mortality outcomes (death from any cause) and adverse events of g-csf in the treatment of newborns with neonatal sepsis and neutropenia [absolute neutrophil count (anc)<5,000 mm³] compared to the conventional therapy?¹

Answer: In newborns with sepsis and neutropenia

≤5,000 cells/mm³, the use of g-csf reduces the risk of in-hospital death by 19% (nnt = 5). G-csf has proved to be a safe drug.

REFERENCES

1. Silvinato A, Bernardo WB, Floriano I – Neonatal sepsis with neutropenia: granulocyte colony stimulating factor (G-CSF) - REV ASSOC MED BRAS 2020; 66(1):3-10.

